Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system-Reference-Cited by-同舟云学术

Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system

Published:2023-07 Issue:7 Volume:23 Page:806-815
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Lewnard Joseph A,McLaughlin John M,Malden Debbie,Hong Vennis,Puzniak Laura,Ackerson Bradley K,Lewin Bruno J,Kim Jeniffer S,Shaw Sally F,Takhar Harpreet,Jodar Luis,Tartof Sara Y

Funder

National Institutes of Health

Centers for Disease Control and Prevention

National Institute of Allergy and Infectious Diseases

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference25 articles.

1. Antibody evasion properties of SARS-CoV-2 omicron sublineages;Iketani;Nature,2022

2. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19;Hammond;N Engl J Med,2022

3. Nirmatrelvir use and severe COVID-19 outcomes during the omicron surge;Arbel;N Engl J Med,2022